Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 3860 results
Eli Lilly gets FDA approval for gastric cancer combination drug
By PBR Staff Writer
Eli Lilly and Company has received the US Food and Drug Administration (FDA) approval for Cyramza (ramucirumab) in combination with paclitaxel (a type of chemotherapy) to treat advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma.
Drug Research > Drug Discovery & Development > News
Genzyme enrolls first patient in Phase II vatelizumab trial in RRMS patients
By PBR Staff Writer
Sanofi's Genzyme has started enrolling patients in a multicenter Phase II clinical trial (EMPIRE) of its investigational infusion therapy vatelizumab in patients with relapsing remitting multiple sclerosis (RRMS).
Drug Research > Drug Discovery & Development > News
Abide Therapeutics partners with Oxford University on new drug targets
By PBR Staff Writer
US-based Abide Therapeutics has entered into a collaborative agreement with the University of Oxford and the Oxford University Hospitals NHS Trust to explore the therapeutic potential of serine hydrolases in diseases of the central nervous system (CNS).
Drug Research > Drug Discovery & Development > News
OptiNose reports pivotal phase III results for migraine treatment developed using bi-directional breath powered technology
OptiNose announced that the TARGET study – a pivotal phase III study evaluating the efficacy and safety of AVP-825, will be published in the January 2015 issue of Headache, The Journal of Head and Face Pain, the official journal of the American Headache Society.
Drug Research > Drug Discovery & Development > News
LCT completes patient enrollment in Phase I/IIa trial for Parkinson's disease
By PBR Staff Writer
Australasian biotechnology firm Living Cell Technologies (LCT) has completed patient enrollment in a Phase I/IIa clinical trial of the regenerative cell therapy NTCELL for Parkinson’s disease.
Drug Research > Drug Discovery & Development > News
MEI Pharma begins dosing in ME-344 Phase Ib trial for small cell lung and ovarian cancers
By PBR Staff Writer
US-based MEI Pharma has dosed the first patient in a cohort-expansion stage of its Phase Ib clinical trial of ME-344 in combination with topotecan to treat patients with small cell lung or ovarian cancer who failed initial therapy.
Drug Research > Drug Discovery & Development > News
Relmada adds $15m in capital to accelerate development of pain treatment drugs
Relmada Therapeutics, a biopharmaceutical firm with four novel pain treatment drugs currently under development in its pipeline, has received a healthy injection of more than $15m in capital last week that will assist the company in the advancement of its work to bring those products to the largest drug prescription market in the world - the treatment of pain.
Drug Research > Drug Discovery & Development > News
Aileron Therapeutics secures $33m in series E financing to advance cancer drug development
Aileron Therapeutics, a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, has announced that it has secured $33m in an extension to its Series E equity financing, bringing the total raised in this round to $48m.
Drug Research > Drug Discovery & Development > News
Akebia reports positive top-line results from Phase IIb AKB-6548 anemia trial
By PBR Staff Writer
Akebia Therapeutics has reported positive top-line results from its Phase IIb placebo-controlled trial of its once-daily, oral therapy, AKB-6548, in non-dialysis patients with anemia related to chronic kidney disease (CKD).
Drug Research > Drug Discovery & Development > News
Imprimis reports positive clinical findings of dropless cataract surgery
Imprimis Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, has reported clinical findings demonstrating the safety and benefits of Dropless cataract surgery and provided an update resulting from the recent American Academy of Ophthalmology (AAO) annual meeting held in Chicago, Illinois.
Drug Research > Drug Discovery & Development > News
Vaxart accelerates Ebola tablet vaccine development
Vaxart, a privately held company developing vaccines that are administered by tablet rather than by injection, has announced that the company is accelerating its Ebola tablet vaccine program.
Drug Research > Drug Discovery & Development > News
MabVax Therapeutics nominates HuMab 5B1 as lead clinical development candidate
MabVax Therapeutics Holdings, a clinical stage oncology drug development company, has formally nominated its HuMab 5B1 antibody as a clinical candidate for the diagnosis and treatment of pancreatic and colon cancer.
Drug Research > Drug Discovery & Development > News
Immunotech completes negotiations with Uldic to market potential Ebola treatment in Africa
By PBR Staff Writer
Immunotech Laboratories has completed negotiations with Zimbabwe-based Uldic Investment (Uldic) to pursue the development of market opportunities related to potential treatment of the deadly Ebola virus in Sub-Saharan West Africa.
Drug Research > Drug Discovery & Development > News
Apricus expands development pipeline with in-licensing of US rights for fispemifene
Apricus Biosciences has licensed the U.S. development and commercialization rights for a novel selective estrogen receptor modulator ("SERM"), fispemifene, an investigational treatment for urological conditions in men, from Forendo Pharma, a private therapeutics company based in Finland.
Drug Research > Drug Discovery & Development > News
EYLEA injection shows better gains in visual acuity than both bevacizumab and ranibizumab in NIH-sponsored DME study
Regeneron Pharmaceuticals, has announced that in the National Institutes of Health (NIH) sponsored, Diabetic Retinopathy Clinical Research Network comparative effectiveness study in patients with Diabetic Macular Edema (Protocol T), EYLEA (aflibercept) Injection demonstrated a significantly greater improvement in mean change in best-corrected visual acuity (BCVA) from baseline at 52 weeks compared to both bevacizumab (Avastin/Genentech) and ranibizumab injection (Lucentis/Genentech), the primary endpoint of the study.
Drug Research > Drug Discovery & Development > News
61-75 of 3860 results